Pembrolizumab and Lenvatinib for recurrent endometrial cancer that has progressed after first-line therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional study evaluates the effectiveness and safety of pembrolizumab plus lenvatinib in patients with recurrent endometrial cancer that is mismatch repair-proficient and has progressed after first-line maintenance immunotherapy. Eligible participants have measurable disease and adequate performance status, and must have completed prior treatment with a carboplatin-based doublet followed by immunotherapy. The study will monitor tumor response by RECIST 1.1 and track safety signals related to the drug combination. Enrollment is conducted at the University of Miami and will include patients who have or have not received prior radiation therapy. Prior sequencing of tumor samples may be used to inform participation.”,

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed recurrent endometrial carcinoma, including serous, endometrioid, carcinosarcoma, clear cell subtypes, with measurable disease per RECIST 1.1 criteria.
2. Mismatch repair (MMR) proficient status confirmed by immunohistochemistry (IHC) or molecular testing.
3. Patients must have progressed on or after first-line maintenance immunotherapy that was started while on carboplatin-based doublet chemotherapy and continued following chemotherapy until completion (prior chemotherapy for this disease administered before the most recent line is permitted).
4. Prior radiation is permitted but not required.
5. Patient must have completed next-generation sequencing on either primary or recurrent tumor.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.
7. Age ≥ 18 years.
8. Female participants must be of non-childbearing potential or for females of child bearing potential (FOCBPs), must agree to use contraception as described in protocol. FOCBPs must not be pregnant or breastfeeding.
9. At least one measurable lesion according to RECIST 1.1.
10. Adequate organ function, including:

    * Hemoglobin ≥ 8 g/dL (blood transfusions are permitted)
    * Absolute neutrophil count ≥ 1000
    * Platelet count ≥ 100 x 10⁹/L
    * Glomerular filtration rate (GFR) ≥ 30 mL/min
    * Bilirubin ≤ 1.5 x ULN (upper limit of normal)
11. Written informed consent obtained from the patient.
12. At least 3 weeks must have elapsed from any prior therapy

Exclusion Criteria:

1. Uterine sarcoma
2. Active central nervous system metastases or leptomeningeal disease.
3. History of severe allergic reactions to pembrolizumab, lenvatinib, or any components of the formulations.
4. Active autoimmune disease requiring chronic systemic steroids for \> 3 months in the last 6 months prior to enrollment.
5. Pregnancy or breastfeeding at the time of enrollment.
6. Previous treatment with lenvatinib or other VEGFR inhibitors.
7. Concurrent treatment with other investigational drugs or anti-cancer therapies except for adjuvant hormonal therapy for breast cancer.
8. Uncontrolled concurrent illness, such as active infections that could interfere with study participation.
9. Blood pressure \>160 systolic or \>110 diastolic averaged over last 3 documented measurements.
10. History of significant cardiovascular events within 12 months prior to enrollment, including myocardial infarction, unstable angina, or congestive heart failure (NYHA Class III or IV).
11. History of organ transplant or immune suppressive therapy that would interfere with the efficacy or safety of the investigational drugs.
12. Other malignancies within the past 2 years except for non-melanoma skin cancer.
13. Patients that have received more than one prior line of immunotherapy.

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Navya Nair, MD, MPH — University of Miami
• Study coordinator: Navya Nair, MD, MPH
• Email: navya.nair@miami.edu
• Phone: 305-243-2233

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Pembrolizumab plus lenvatinib for vulvar cancer (MITO VULVA-01)

  This trial will test whether combining pembrolizumab with lenvatinib helps people with advanced, recurrent, or unresectable vulvar cancer.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples · NCT07290894

• Combination therapy of pembrolizumab and lenvatinib for unresectable cutaneous angiosarcoma

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help people with a type of skin cancer called unresectable cutaneous angiosarcoma who haven't had success with other treatments.

  Recruiting at 6 sites Phase 2 National Cancer Center, Japan · Kashiwa and 5 other locations · NCT06673628

• Lenvatinib plus pembrolizumab for anal or rectal cancer that progressed after first treatment

  This trial gives lenvatinib with pembrolizumab to people whose anorectal squamous cell cancer has spread or gotten worse after first-line chemotherapy or chemoradiation to see if the combination controls the cancer and is safe.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois · NCT06669572

• Evaluating biomarkers in advanced biliary tract cancer treatment with lenvatinib and pembrolizumab

  This study is testing if a combination of two drugs, lenvatinib and pembrolizumab, can help people with advanced biliary tract cancer and is looking for clues in their genetic data to see how well the treatment works.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT06648057

• Combining Pembrolizumab and Lenvatinib for Anaplastic Thyroid Cancer

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help people with anaplastic thyroid cancer who haven't been treated before.

  Recruiting Phase 2 Saint Petersburg State University, Russia · Saint Petersburg · NCT06374602

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.